SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is heavily discussed as its earnings report looms, with the community sharply divided between strong bullish expectations driven by soaring AI-related memory demand and fears of a post-earnings sell-off mirroring recent reactions in the broader semiconductor sector. Many believe robust demand and rising memory prices will lead to a strong report, but sector-wide profit-taking after strong earnings remains a key concern.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals is actively trending after announcing positive preliminary Phase 2 data for its NGC-Cap treatment in metastatic breast cancer, demonstrating increased drug efficacy without additional side effects. This crucial update, combined with the company's low share float following a recent reverse split, has fueled intense trading volume and multiple circuit breaker halts. The community is buzzing with bullish sentiment, anticipating substantial price appreciation, though some express caution regarding the stock's volatility and historical patterns.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group (GRRR) is trending following multiple analyst upgrades, notably a "strong-buy" rating from Cantor Fitzgerald with a significant price target, signaling growing confidence in its future. Additionally, an ongoing lawsuit against alleged market manipulators is drawing community attention as a fight to stabilize the stock's valuation. Investors are actively debating the company's substantial contract pipeline and projected revenue growth against concerns over past stock performance and alleged manipulation, with many highlighting GRRR's perceived undervaluation and low float amidst broader AI sector volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing intense debate and price volatility following reports of a California court ruling challenging its "Full Self-Driving" branding, raising questions about the company's autonomous technology claims. This fuels widespread discussion, with bears pointing to market overvaluation and FSD limitations, while many bulls remain confident in a rebound to recent highs. The strong contrasting perspectives highlight ongoing investor focus on Tesla's future technology and broader market movements.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following news of its expanded Korea Battery Alliance and a Nokia partnership, significantly boosting its global production capacity for high-energy-density batteries. The community is also buzzing about a potential Amazon deal, while many investors view current price dips as a buying opportunity, confident in the company's strong fundamentals and long-term potential despite broader market volatility affecting growth stocks. This conviction underscores a belief in its leadership in the electric aviation and drone sectors.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is experiencing extreme volatility amid speculation surrounding GE Vernova's entry into the fuel cell space and broader market sentiment shifts regarding AI-driven data center spending. The community is sharply divided, with some attributing the sharp price drops to institutional manipulation and tax-loss harvesting, while others see these dips as prime buying opportunities given the company's strong long-term fundamentals in clean energy infrastructure.

Mega Fortune Co., Ltd. operates as an investment holding company. It specializes in delivering comprehensive IoT solutions and services across various industries. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited (MGRT), a recent Hong Kong-based IoT IPO, is experiencing intense speculative interest driven by its low float and reported insider lock-up, drawing comparisons to other volatile Asian listings. The stock is seeing rapid price swings and frequent trading halts, prompting community discussions around its potential for significant short-term gains or swift corrections. Traders are closely watching key price levels as retail attention focuses on this high-risk, high-reward momentum play.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending following its announcement of a new AI infrastructure partnership with Anthropic and Fluidstack, which includes a substantial data center lease agreement with reported backing from Google. The community is buzzing about this strategic pivot, seeing it as a transformative move from primarily Bitcoin mining into the high-demand AI sector and a catalyst for diversified revenue streams. Many anticipate a significant re-evaluation of the company's future potential.

Medline, Inc. engages in the provision of medical-surgical products and supply chain solutions. It operates through the Medline Brand and Supply Chain Solutions segments. The Medline Brand segment is involved in the procurement and manufacture of products from surgical solutions, front line care, and laboratory and diagnostics categories. The Supply Chain Solutions segment focuses on procurement and distribution of a variety of third-party products from national brands and provides tailored logistics and supply chain optimization services to domestic and international consumers. The company was founded by Jim Mills and Jon Mills in 1966 and is headquartered in Northfield, IL.

Medline Inc - Ordinary Shares - Class A

Medline Inc.

Medline is trending following its significant market debut, hailed as 2025's largest IPO, which saw its stock soar immediately. The community is actively discussing its long-term potential as an essential medical supplier, with many anticipating substantial gains, while others express frustration over limited IPO allocations and highlight the company's considerable debt.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is experiencing significant market attention driven by expectations of an imminent executive order to reclassify cannabis to Schedule III. Community discussions are highly polarized, anticipating a major short squeeze and substantial upward movement, while others caution about the direct benefits for Canadian-based operators versus US multi-state cannabis companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AGNPF Algernon Pharmaceuticals reports results of study on ifenprodil 
 
Algernon Pharmaceuticals reports that ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. The multi-dose study was conducted under the direction of Seyltx, a private US-based drug development company which recently acquired Algernon&#39;s ifenprodil research program for the purchase price of $2M USD and a 20% equity position. The study was designed to inform dose selection in Seyltx&#39;s planned Phase 2b ifenprodil human study, recently named SILINDA, in refractory chronic cough. Seyltx has also announced that patient enrollment in the study is expected to begin in early 2025. Ifenprodil is an N-methyl-D-aspartate receptor antagonist specifically targeting the NR2B subunit, which prevents glutamate signalling.  
 
Ifenprodil represents a first-in-class potential treatment for chronic cough and interferes with central signalling in the brain, supressing the urge to cough. The near-complete suppression of cough was observed in animals receiving a dose of 30 mg/kg, in a dose-dependent manner, below the no observed adverse effect level dose. Other dosing arms included 1, 3, and 10 mg/kg. A clear and statistically significant dose response was observed. The full results of the study will be presented at the London International Cough Symposium July 18th - 19th, 2024. In an earlier Algernon Phase 2a clinical trial measuring cough in patients with idiopathic pulmonary fibrosis, ifenprodil, 20 mg TID, reduced cough by ~40% from baseline.

StockTwits Web

Algernon Pharmaceuticals Inc

 Algernon Pharmaceuticals reports results of study on ifenprodil 
 
Algernon Pharmaceuticals reports that ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. The multi-dose study was conducted under the direction of Seyltx, a private US-based drug development company which recently acquired Algernon's ifenprodil research program for the purchase price of $2M USD and a 20% equity position. The study was designed to inform dose selection in Seyltx's planned Phase 2b ifenprodil human study, recently named SILINDA, in refractory chronic cough. Seyltx has also announced that patient enrollment in the study is expected to begin in early 2025. Ifenprodil is an N-methyl-D-aspartate receptor antagonist specifically targeting the NR2B subunit, which prevents glutamate signalling.  
 
Ifenprodil represents a first-in-class potential treatment for chronic cough and interferes with central signalling in the brain, supressing the urge to cough. The near-complete suppression of cough was observed in animals receiving a dose of 30 mg/kg, in a dose-dependent manner, below the no observed adverse effect level dose. Other dosing arms included 1, 3, and 10 mg/kg. A clear and statistically significant dose response was observed. The full results of the study will be presented at the London International Cough Symposium July 18th - 19th, 2024. In an earlier Algernon Phase 2a clinical trial measuring cough in patients with idiopathic pulmonary fibrosis, ifenprodil, 20 mg TID, reduced cough by ~40% from baseline.